Phase II study (NCT03381781) decitabine, cytarabine (Ara-C) and arsenic trioxide (ATO) in the treatment of acute myeloid leukemia with p53 mutations is designed to sequence one thousand five hundred MDS/AML patients and randomize around one hundred patients with TP53 mutations for the treatment. This evidence concerns the gene TP53 and acute myeloid leukemia.